All In Biotech

Drug Trial Radar · NCT06049212

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Phase 1 Trial of MK-2870 as Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Subjects With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Oct 26, 2023

Primary completion

Dec 31, 2027

Study completion Jan 29, 2028

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Sep 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1 trial of the safety, tolerability, and pharmacokinetics (PK) of sacituzumab tirumotecan monotherapy, and of sacituzumab tirumotecan in combination with pembrolizumab (MK-3475) or pembrolizumab + carboplatin, in Japanese participants with advanced solid tumors or treatment-naïve advanced or metastatic non-small cell lung cancer (NSCLC). Per protocol amendment 04, Arm 3: Pembrolizumab/Carboplatin + sacituzumab tirumotecan Combination Therapy was discontinued, and subsequently all Arm 3 procedures, recruitment, and descriptions were removed.

Conditions

  • Non-small Cell Lung Cancer
  • Solid Tumors
  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
  • Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)

Interventions

  • Sacituzumab tirumotecanBiological

    Sacituzumab tirumotecan injection powder for intravenous (IV) infusion.

  • PembrolizumabBiological

    Pembrolizumab solution for IV infusion.

  • Supportive care measuresDrug

    Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Dose-Limiting Toxicity (DLT)Time frame: Up to 21 days after each dose
  2. Number of Participants Experiencing ≥1 Adverse Event (AE)Time frame: Up to ~32 months
  3. Number of Participants Discontinuing from Study Therapy due to AETime frame: Up to ~32 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Aichi Cancer Center ( Site 0006)

    Nagoya, Aichi-ken, Japan

  • National Cancer Center Hospital East ( Site 0002)

    Kashiwa, Chiba, Japan

  • National Hospital Organization Shikoku Cancer Center ( Site 0008)

    Matsuyama, Ehime, Japan

  • Kanagawa Cancer Center ( Site 0004)

    Yokohama, Kanagawa, Japan

  • Kansai Medical University Hospital ( Site 0007)

    Hirakata, Osaka, Japan

  • Shizuoka Cancer Center ( Site 0005)

    Nagaizumi-cho,Sunto-gun, Shizuoka, Japan

  • National Cancer Center Hospital ( Site 0001)

    Chuo-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.